Patent ID: 11945848
Assignee: OMEROS CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 0:
1. A method of treating a subject suffering from an autoimmune disorder comprising administering a composition comprising a chimeric molecule of a ficolin-associated polypeptide, wherein said chimeric molecule of a ficolin-associated polypeptide comprises: (a) a human ficolin-associated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:1; and (b) an inhibitor of complement activation, wherein said inhibitor of complement activation is selected from the list consisting of Factor H (FH), GAS6, Protein S, C1-inhibitor (C1-inh), complement component 4 binding protein (C4 bp), Factor I (FI), CR1, DAF(CD55), CD59, CR2, or a fragment thereof that inhibits complement activation, or an immunoglobulin molecule or part thereof that is an inhibitor of complement activation, and wherein said chimeric molecule inhibits complement activation in a subject suffering from an autoimmune disorder, wherein said autoimmune disorder is selected from the group consisting of Addison's disease, autoimmune hemolytic anemia, autoimmune thyroiditis, Crohn's disease, Graves' disease, Guillain-Barre syndrome, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, myasthenia gravis, psoriasis, primary biliary cirrhosis, rheumatoid arthritis, uveitis, asthma, atherosclerosis, type I diabetes, and allergies.